CY1108734T1 - Αναπτυξη αντισωματων ειδικων για hcv - Google Patents

Αναπτυξη αντισωματων ειδικων για hcv

Info

Publication number
CY1108734T1
CY1108734T1 CY20091100101T CY091100101T CY1108734T1 CY 1108734 T1 CY1108734 T1 CY 1108734T1 CY 20091100101 T CY20091100101 T CY 20091100101T CY 091100101 T CY091100101 T CY 091100101T CY 1108734 T1 CY1108734 T1 CY 1108734T1
Authority
CY
Cyprus
Prior art keywords
hcv
antibodies
development
specific antibodies
nob
Prior art date
Application number
CY20091100101T
Other languages
Greek (el)
English (en)
Inventor
Michael Houghton
Mark Selby
Sergio Abrignani
Jens Heile
Hagan Derek O´
Original Assignee
Novartis Vaccines And Diagnostics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines And Diagnostics, Inc. filed Critical Novartis Vaccines And Diagnostics, Inc.
Publication of CY1108734T1 publication Critical patent/CY1108734T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CY20091100101T 1999-12-01 2009-01-27 Αναπτυξη αντισωματων ειδικων για hcv CY1108734T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16823499P 1999-12-01 1999-12-01
US18505500P 2000-02-25 2000-02-25
EP00993586A EP1233782B1 (en) 1999-12-01 2000-12-01 Eliciting hcv-specific antibodies

Publications (1)

Publication Number Publication Date
CY1108734T1 true CY1108734T1 (el) 2014-04-09

Family

ID=26863907

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100101T CY1108734T1 (el) 1999-12-01 2009-01-27 Αναπτυξη αντισωματων ειδικων για hcv

Country Status (12)

Country Link
US (3) US7329408B2 (https=)
EP (1) EP1233782B1 (https=)
JP (1) JP2004500366A (https=)
AT (1) ATE413190T1 (https=)
AU (1) AU5442501A (https=)
CA (1) CA2393251C (https=)
CY (1) CY1108734T1 (https=)
DE (1) DE60040755D1 (https=)
DK (1) DK1233782T3 (https=)
ES (1) ES2319727T3 (https=)
PT (1) PT1233782E (https=)
WO (1) WO2001047551A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2389206C (en) * 1999-10-27 2011-01-04 Chiron Corporation Activation of hcv-specific t cells
JP2004500366A (ja) * 1999-12-01 2004-01-08 カイロン　コーポレイション Ｃ型肝炎ウイルス（ｈｃｖ）について特異的な抗体を誘発すること
AUPQ797700A0 (en) * 2000-06-06 2000-06-29 Austin Research Institute, The Vaccine
CZ20033515A3 (cs) * 2001-06-29 2005-01-12 Chiron Corporation Kompozice vakcíny HCV E1E2
CU23244A1 (es) * 2001-07-16 2007-10-17 Ct Ingenieria Genetica Biotech Formulacion vacunal potenciada por la combinacion de un adn con un antigeno
CA2461380C (en) 2001-10-11 2011-03-22 Merck & Co., Inc. Hepatitis c virus vaccine
AU2003299994A1 (en) * 2002-12-27 2004-07-29 Chiron Corporation Immunogenic compositions containing phospholpid
US20050191358A1 (en) * 2003-01-14 2005-09-01 Derek O' Hagan Microparticles with adsorbed polynucleotide-containing species
WO2004071414A2 (en) * 2003-02-05 2004-08-26 Genzyme Corporation Therapeutic anti-hcv (al9) compounds
US20040203084A1 (en) * 2003-04-10 2004-10-14 Doug Levinson Profiling conformational variants, antibody compositions and methods of using the same
CA2523266A1 (en) * 2003-04-25 2004-11-11 Chiron Corporation Compositions comprising cationic microparticles and hcv e1e2 dna and methods of use thereof
EP1631264B8 (en) * 2003-06-02 2017-05-24 GlaxoSmithKline Biologicals SA Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
NZ551319A (en) * 2004-05-17 2010-07-30 Novartis Vaccines & Diagnostic Truncated Hepatitis C virus NS5 domain and fusion proteins comprising same
AU2005294805B2 (en) 2004-05-28 2012-02-16 Oryxe A mixture for transdermal delivery of low and high molecular weight compounds
PT1801209E (pt) 2004-08-24 2011-05-26 Toray Industries Arn gen?mico do v?rus humano modificado da hepatite c com capacidade de replica??o aut?noma
EP1820856B1 (en) * 2004-11-18 2011-04-27 National University of Corporation Hiroshima University Method and kit for expressing protein under regulation of the expression from repeated sequence formed by gene amplification and transformant
EP1981537B1 (en) * 2006-01-04 2015-08-26 GlaxoSmithKline Biologicals S.A. HCV E1E2 MF59-adjuvanted protein plus HCV E1E2 encoding alphavirus vector for eliciting HCV-specific T cells.
CA2694397A1 (en) 2007-07-25 2009-01-29 Japan As Represented By Director-General Of National Institute Of Infect Ious Diseases Antibody having inhibitory activity on infection with hepatitis c virus (hcv) and use thereof
WO2011052735A1 (ja) 2009-10-30 2011-05-05 東レ株式会社 C型肝炎ウイルス（hcv）に対して感染阻害活性を有する抗体及びその用途
CN104324373B (zh) * 2010-11-26 2018-10-09 麦克法兰博尼特医学健康研究公司 组合物及其制备方法
CN111437395A (zh) 2013-08-29 2020-07-24 希望之城 细胞穿透缀合物及其使用方法
KR20180053318A (ko) 2015-09-17 2018-05-21 제이알엑스 바이오테크놀로지, 인코포레이티드 피부 수화 또는 보습을 향상시키기 위한 접근법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ227011A (en) * 1987-11-18 1992-03-26 Chiron Corp Non-a, non-b-hepatitis (hepatitis c) antigens, proteins, nucleotide sequences, vaccines and kits
US5350671A (en) 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
US5471330A (en) 1993-07-29 1995-11-28 Honeywell Inc. Polysilicon pixel electrode
EP1510580B1 (en) 1994-07-29 2008-12-10 Novartis Vaccines and Diagnostics, Inc. Hepatitis C E2 truncated polypeptide and methods of obtaining the same
AU3241095A (en) * 1994-07-29 1996-03-04 Chiron Corporation Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same
GB9416671D0 (en) 1994-08-17 1994-10-12 Biocine Spa Assay
US6019980A (en) * 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
DE69608122T3 (de) * 1995-11-09 2011-06-16 Microbiological Research Authority Camr, Salisbury Mikroverkapselte dna zur impfung und gentherapie
US5939400A (en) * 1996-02-26 1999-08-17 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for induction of suppressive T cell response
CA2288374A1 (en) 1997-05-06 1998-11-12 Chiron Corporation Intracellular production of hepatitis c e1 and e2 truncated polypeptides
CA2296089A1 (en) * 1997-07-18 1999-01-28 Connaught Laboratories Limited Nucleic acid vaccines encoding g protein of respiratory syncytial virus
ES2175668T3 (es) * 1997-12-16 2002-11-16 Chiron Corp Uso de microparticulas combinadas con emulsiones de aceite en agua submicronicas.
CA2389206C (en) 1999-10-27 2011-01-04 Chiron Corporation Activation of hcv-specific t cells
JP2004500366A (ja) * 1999-12-01 2004-01-08 カイロン　コーポレイション Ｃ型肝炎ウイルス（ｈｃｖ）について特異的な抗体を誘発すること

Also Published As

Publication number Publication date
US20080095800A1 (en) 2008-04-24
AU5442501A (en) 2001-07-09
ES2319727T3 (es) 2009-05-12
ATE413190T1 (de) 2008-11-15
US7329408B2 (en) 2008-02-12
EP1233782A2 (en) 2002-08-28
US20020002272A1 (en) 2002-01-03
EP1233782B1 (en) 2008-11-05
WO2001047551A2 (en) 2001-07-05
US20110159039A1 (en) 2011-06-30
DE60040755D1 (de) 2008-12-18
JP2004500366A (ja) 2004-01-08
CA2393251A1 (en) 2001-07-05
DK1233782T3 (da) 2009-02-09
WO2001047551A3 (en) 2002-03-14
CA2393251C (en) 2012-01-31
PT1233782E (pt) 2009-02-13

Similar Documents

Publication Publication Date Title
CY1108734T1 (el) Αναπτυξη αντισωματων ειδικων για hcv
DK0693687T3 (da) Kombinationer af hepatitis C-virus (HCV)-antigener til anvendelse i immunoassays for anti-HCV-antistoffer
NZ545048A (en) Chimeric antigens for breaking host tolerance to foreign antigens
IL152825A0 (en) Rabies virus-specific neutralizing human monoclonal antibodies and nucleic acids and related methods
HUP0303134A3 (en) Hiv peptides, antigens, vaccine compositions, immunoassay kits and method of detecting antibodies induced by hiv
ATE17320T1 (de) Impfstoff, therapie gegen nicht-a nicht-b virale hepatitis und verfahren zur herstellung desselben.
EP1200109A4 (en) USE OF PEPTIDE NUCLEIC ACID COMPOUNDS TO TRIGGER CELLULAR IMMUNE RESPONSES TO HEPATITIS C
AU6616301A (en) Modification of hepatitis b core antigen
WO1993001210A3 (de) Hcv peptidantigene und verfahren zur bestimmung von hcv
DK0623169T3 (da) Hepatitis E virus og fremgangsmåde
DE69532062D1 (de) Immuntests von nicht-A, nicht-B Hepatitisvirus-verwandten Antigenen, monoklonale Antikörper und diese synthetisierende Hybridome
DE69531235D1 (de) Säugetier - Expressionssysteme für Hüllenprotingene des Hepatitit - C - Virus
EP1301208A4 (en) Vaccine
NO20051715L (no) HCV assay
DK1417233T3 (da) Humant rekombinant antistof mod det hepatitis C (HCV) ikke-strukturelle NS3-protein, nukleinsyre og anvendelser deraf
RU2008114385A (ru) ИНДУКТОР СЕКРЕТОРНЫХ АНТИТЕЛ IgA И IgG
EP0339668A3 (en) Hepatitis a virus antigen
DK0556320T3 (da) Monoklonale antistoffer mod Hepatitis C-virus og fremgangsmåde til anvendelse heraf
DK0599913T3 (da) Monoklonale antistoffer mod formodet hepatitis C-virus NS5-proteiner og anvendelsesmetoder af samme
DK230090D0 (da) Peptider
DE68918440D1 (de) Verfahren zur transformation von menschlichen b-lymphocyten.
WO2003014728A1 (fr) Medicaments contre l'hepatite c
DK375388D0 (da) Nanb hepatitisvirusmiddel, antigen og immunologisk reagens
DE69331796D1 (de) Kernantigenprotein des Hepatitis C-Virus, sowie diagnostisches Verfahren und Satz von Reagenzen
TH22297A (th) การวินิจฉัย nanbv และวัคซีน